• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature.

作者信息

Niesert Anne-Charlotte, Guertler Anne, Schutti Olga, Engels Laura, Flaig Michael, French Lars E, Schlaak Max, Reinholz Markus

机构信息

Department of Dermatology and Allergy, University Hospital, LMU Munich, DE-80337 Munich, Germany. E-mail:

出版信息

Acta Derm Venereol. 2021 Jun 2;101(6):adv00472. doi: 10.2340/00015555-3840.

DOI:10.2340/00015555-3840
PMID:34043014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9380279/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b02d/9380279/3a71677194f6/ActaDV-101-6-663-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b02d/9380279/3a71677194f6/ActaDV-101-6-663-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b02d/9380279/3a71677194f6/ActaDV-101-6-663-g001.jpg

相似文献

1
Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature.程序性细胞死亡蛋白1抑制剂辅助使用后出现的溃疡性扁平苔藓：一例报告及文献系统综述
Acta Derm Venereol. 2021 Jun 2;101(6):adv00472. doi: 10.2340/00015555-3840.
2
Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.大疱性扁平苔藓与抗程序性细胞死亡-1治疗：病例报告及文献综述
Ann Dermatol Venereol. 2020 Mar;147(3):221-227. doi: 10.1016/j.annder.2019.07.008. Epub 2020 Jan 22.
3
Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.扁平苔藓样天疱疮：一种继发于纳武利尤单抗的独特的水疱性和苔藓样发疹形式。
Dermatol Ther. 2022 May;35(5):e15432. doi: 10.1111/dth.15432. Epub 2022 Mar 15.
4
Lichen-planus-pemphigoides-like reaction to PD-1 checkpoint blockade.PD-1 检查点阻断致扁平苔藓样水疱病样反应。
J Cutan Pathol. 2022 Nov;49(11):978-987. doi: 10.1111/cup.14299. Epub 2022 Aug 23.
5
Reduced expression of programmed cell death 1 and programmed cell death ligand 1 in infiltrating inflammatory cells of lichen planus without administration of immune checkpoint inhibitors.未使用免疫检查点抑制剂的扁平苔藓浸润性炎症细胞中程序性细胞死亡 1 和程序性细胞死亡配体 1 的表达降低。
J Dermatol. 2021 Sep;48(9):1428-1432. doi: 10.1111/1346-8138.15977. Epub 2021 Jun 7.
6
Nivolumab-related lichen planus of the lip in a patient with head and neck cancer.头颈部癌症患者使用纳武利尤单抗相关的唇部扁平苔藓。
Oral Oncol. 2020 May;104:104623. doi: 10.1016/j.oraloncology.2020.104623. Epub 2020 Mar 3.
7
Nivolumab-induced lichen planus pemphigoides.纳武单抗诱发的类天疱疮样扁平苔藓。
Cutis. 2019 Apr;103(4):224-226.
8
Nivolumab-induced lichen planus.纳武单抗诱发的扁平苔藓。
J Oncol Pharm Pract. 2020 Apr;26(3):758-760. doi: 10.1177/1078155219866248. Epub 2019 Aug 5.
9
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
10
Assessment of PD-1 and PD-L1 tissue expression levels in lichen planus patients: a case-control study.评估扁平苔藓患者的 PD-1 和 PD-L1 组织表达水平：一项病例对照研究。
Arch Dermatol Res. 2024 Mar 2;316(3):97. doi: 10.1007/s00403-024-02838-z.

引用本文的文献

1
Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review.一名非小细胞肺腺癌患者中与信迪利单抗治疗相关的苔藓样皮肤黏膜反应：病例报告及文献复习
Front Pharmacol. 2023 Dec 12;14:1276788. doi: 10.3389/fphar.2023.1276788. eCollection 2023.
2
Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.免疫检查点抑制剂诱导的皮肤免疫相关不良事件（irAEs）的分子机制。
Curr Oncol. 2023 Jul 18;30(7):6805-6819. doi: 10.3390/curroncol30070498.
3
Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors.

本文引用的文献

1
Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects.肝细胞癌根治性治疗后的辅助治疗：现状与展望。
Genes Dis. 2020 Feb 29;7(3):359-369. doi: 10.1016/j.gendis.2020.02.002. eCollection 2020 Sep.
2
Immune checkpoint inhibitor-related dermatologic adverse events.免疫检查点抑制剂相关的皮肤不良反应。
J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132. Epub 2020 May 23.
3
Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review.
接受免疫检查点抑制剂治疗的患者发生硬化性苔藓和扁平苔藓的风险。
Int J Environ Res Public Health. 2022 Dec 29;20(1):580. doi: 10.3390/ijerph20010580.
4
Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma.黑色素瘤的免疫治疗：免疫检查点抑制剂在晚期黑色素瘤治疗中的意义。
Int J Mol Sci. 2022 Dec 11;23(24):15720. doi: 10.3390/ijms232415720.
5
Skin Manifestation Induced by Immune Checkpoint Inhibitors.免疫检查点抑制剂诱导的皮肤表现
Clin Cosmet Investig Dermatol. 2022 May 10;15:829-841. doi: 10.2147/CCID.S364243. eCollection 2022.
6
Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.扁平苔藓样天疱疮：一种继发于纳武利尤单抗的独特的水疱性和苔藓样发疹形式。
Dermatol Ther. 2022 May;35(5):e15432. doi: 10.1111/dth.15432. Epub 2022 Mar 15.
大疱性扁平苔藓与抗程序性细胞死亡-1治疗：病例报告及文献综述
Ann Dermatol Venereol. 2020 Mar;147(3):221-227. doi: 10.1016/j.annder.2019.07.008. Epub 2020 Jan 22.
4
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019.欧洲基于共识的跨学科黑色素瘤指南。第二部分：治疗-2019 更新。
Eur J Cancer. 2020 Feb;126:159-177. doi: 10.1016/j.ejca.2019.11.015. Epub 2019 Dec 19.
5
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.一项关于免疫相关不良反应的发生与晚期癌症患者接受检查点抑制剂治疗的临床结局之间新出现关联的系统评价。
Semin Oncol. 2019 Aug-Oct;46(4-5):362-371. doi: 10.1053/j.seminoncol.2019.10.003. Epub 2019 Nov 7.
6
Clinical epidemiology and treatment of lichen planus: A retrospective review of 2 tertiary care centers.扁平苔藓的临床流行病学与治疗：对两家三级医疗中心的回顾性研究
J Am Acad Dermatol. 2019 Dec;81(6):1397-1399. doi: 10.1016/j.jaad.2019.04.027. Epub 2019 Apr 17.
7
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.帕博利珠单抗辅助治疗与安慰剂对照用于 III 期黑色素瘤完全切除术后患者的随机、双盲、III 期临床试验
N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.
8
Clinical assessment of immune-related adverse events.免疫相关不良事件的临床评估
Ther Adv Med Oncol. 2018 Mar 30;10:1758835918764628. doi: 10.1177/1758835918764628. eCollection 2018.
9
Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.免疫检查点抑制剂的皮肤不良反应：皮肤毒性与免疫治疗
Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
10
A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.晚期黑色素瘤治疗的新前沿：在免疫检查点抑制剂时代重新定义临床管理。
Hum Vaccin Immunother. 2017 Aug 3;13(8):1765-1767. doi: 10.1080/21645515.2017.1322241. Epub 2017 May 8.